- Home
- IMCR vs PLYA Comparison
IMCR vs PLYA Comparison
Compare IMCR & PLYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- PLYA
- Stock Information
- Founded
- IMCR 2008
- PLYA 2006
- Country
- IMCR United Kingdom
- PLYA Netherlands
- Employees
- IMCR N/A
- PLYA N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- PLYA Hotels/Resorts
- Sector
- IMCR Health Care
- PLYA Consumer Discretionary
- Exchange
- IMCR Nasdaq
- PLYA Nasdaq
- Market Cap
- IMCR 1.5B
- PLYA 1.6B
- IPO Year
- IMCR 2021
- PLYA N/A
- Fundamental
- Price
- IMCR $28.40
- PLYA $13.44
- Analyst Decision
- IMCR Buy
- PLYA Hold
- Analyst Count
- IMCR 11
- PLYA 5
- Target Price
- IMCR $59.11
- PLYA $12.00
- AVG Volume (30 Days)
- IMCR 265.8K
- PLYA 2.3M
- Earning Date
- IMCR 05-07-2025
- PLYA 05-05-2025
- Dividend Yield
- IMCR N/A
- PLYA N/A
- EPS Growth
- IMCR N/A
- PLYA 8.44
- EPS
- IMCR N/A
- PLYA 0.49
- Revenue
- IMCR $333,581,000.00
- PLYA $896,462,000.00
- Revenue This Year
- IMCR $20.26
- PLYA N/A
- Revenue Next Year
- IMCR $8.49
- PLYA $7.68
- P/E Ratio
- IMCR N/A
- PLYA $27.64
- Revenue Growth
- IMCR 25.75
- PLYA N/A
- 52 Week Low
- IMCR $23.15
- PLYA $6.95
- 52 Week High
- IMCR $62.22
- PLYA $13.43
- Technical
- Relative Strength Index (RSI)
- IMCR 45.68
- PLYA 63.16
- Support Level
- IMCR $27.88
- PLYA $13.42
- Resistance Level
- IMCR $31.38
- PLYA $13.45
- Average True Range (ATR)
- IMCR 1.60
- PLYA 0.02
- MACD
- IMCR -0.08
- PLYA -0.00
- Stochastic Oscillator
- IMCR 22.19
- PLYA 80.00
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About PLYA Playa Hotels & Resorts N.V.
Playa Hotels & Resorts NV acts as an owner, operator, and developer of all-inclusive resorts in prime beachfront locations in popular vacation destinations in Mexico and the Caribbean. The company's segments are Yucatan Peninsula, Pacific Coast, Dominican Republic, and Jamaica. It generates a majority of its revenue from the Yucatan Peninsula segment. Its brand profile consists of HYATT ZIVA, HYATT ZILARA, Hilton, JEWEL RESORTS, and others.